MF59 Adjuvanted Molecular Clamp Stabilized SARS-CoV-2 Spike Protein Vaccine

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A vaccine composed of a molecular clamp stabilized form of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein (SP) combined with a squalene-based vaccine adjuvant, MF59, with potential immunomodulating and anti-COVID-19 activities. Upon administration of MF59 adjuvanted molecular clamp stabilized SARS-CoV-2 SP vaccine, the SARS-CoV-2 SP activates the immune system to produce anti-SARS-CoV-2 SP antibodies and T-cell responses against SARS-CoV-2 SP. The antibodies recognize the SP and kill SARS-CoV-2. This prevents SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus. The molecular clamp holds the SARS-CoV-2 SP in the otherwise unstable prefusion position, which may generate a more robust antibody response. The adjuvant strongly stimulates both T-cell and antibody immune responses when combined with the molecular clamp stabilized SARS-CoV-2 SP.

**Synonyms:** - MF59 Adjuvanted Molecular Clamp Stabilized SARS-CoV-2 SP Vaccine - MF59 Adjuvanted SARS-CoV-2 Sclamp Vaccine